Pharmacological Treatment of Gastritis: A Narrative Review with a Systematic Literature Search.

IF 3.4 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Gut and Liver Pub Date : 2025-07-18 DOI:10.5009/gnl250267

Bokyung Kim, Jung Huh, Sang Gyun Kim, Ji Yong Ahn, Ji Won Kim

{"title":"Pharmacological Treatment of Gastritis: A Narrative Review with a Systematic Literature Search.","authors":"Bokyung Kim, Jung Huh, Sang Gyun Kim, Ji Yong Ahn, Ji Won Kim","doi":"10.5009/gnl250267","DOIUrl":null,"url":null,"abstract":"Gastritis, characterized by gastric mucosal inflammation, is a common gastrointestinal disorder with diverse etiologies, such as Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs use, and autoimmune conditions. Pharmacological treatment aims primarily to heal the mucosa and resolve symptoms, and such treatments include mucoprotective agents, histamine-2 receptor antagonists (H2RAs), proton pump inhibitors (PPIs), and potassium-competitive acid blockers (P-CABs). Mucoprotective agents enhance gastric mucosal protection through multiple mechanisms, such as by promoting mucosal regeneration, reducing inflammation, and mitigating oxidative stress. Clinical trials have highlighted the effectiveness of these agents in promoting endoscopic healing and ameliorating symptoms, underscoring the clinical significance of these agents. H2RAs have been extensively used to manage gastritis due to their proven efficacy in reducing gastric acid secretion and promoting mucosal healing. Additionally, PPIs along with newer P-CABs provide robust acid suppression and have shown the ability to rapidly relieve symptoms, thus increasing the number of available treatment options. Since each pharmacological agent offers distinct therapeutic benefits, treatment should be selected based on an individual patient's needs and clinical context.","PeriodicalId":12885,"journal":{"name":"Gut and Liver","volume":" ","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gut and Liver","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5009/gnl250267","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Gastritis, characterized by gastric mucosal inflammation, is a common gastrointestinal disorder with diverse etiologies, such as Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs use, and autoimmune conditions. Pharmacological treatment aims primarily to heal the mucosa and resolve symptoms, and such treatments include mucoprotective agents, histamine-2 receptor antagonists (H2RAs), proton pump inhibitors (PPIs), and potassium-competitive acid blockers (P-CABs). Mucoprotective agents enhance gastric mucosal protection through multiple mechanisms, such as by promoting mucosal regeneration, reducing inflammation, and mitigating oxidative stress. Clinical trials have highlighted the effectiveness of these agents in promoting endoscopic healing and ameliorating symptoms, underscoring the clinical significance of these agents. H2RAs have been extensively used to manage gastritis due to their proven efficacy in reducing gastric acid secretion and promoting mucosal healing. Additionally, PPIs along with newer P-CABs provide robust acid suppression and have shown the ability to rapidly relieve symptoms, thus increasing the number of available treatment options. Since each pharmacological agent offers distinct therapeutic benefits, treatment should be selected based on an individual patient's needs and clinical context.

查看原文本刊更多论文

胃炎的药物治疗：系统文献综述。

胃炎以胃黏膜炎症为特征，是一种常见的胃肠道疾病，病因多样，如幽门螺杆菌感染、非甾体类抗炎药的使用和自身免疫性疾病。药物治疗的主要目的是愈合粘膜和缓解症状，这类治疗包括粘膜保护剂、组胺-2受体拮抗剂（H2RAs）、质子泵抑制剂（PPIs）和钾竞争性酸阻滞剂（p - cab）。粘膜保护剂通过促进粘膜再生、减少炎症、减轻氧化应激等多种机制增强胃粘膜保护。临床试验强调了这些药物在促进内窥镜愈合和改善症状方面的有效性，强调了这些药物的临床意义。由于H2RAs具有减少胃酸分泌和促进粘膜愈合的功效，已被广泛用于治疗胃炎。此外，ppi与较新的p - cab一起提供强大的抑酸作用，并显示出快速缓解症状的能力，从而增加了可用治疗选择的数量。由于每种药理学药物提供不同的治疗效果，治疗应根据个体患者的需要和临床情况来选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Gut and Liver 医学-胃肠肝病学

CiteScore

7.50

自引率

8.80%

发文量

119

审稿时长

6-12 weeks

期刊介绍： Gut and Liver is an international journal of gastroenterology, focusing on the gastrointestinal tract, liver, biliary tree, pancreas, motility, and neurogastroenterology. Gut and Liver delivers up-to-date, authoritative papers on both clinical and research-based topics in gastroenterology. The Journal publishes original articles, case reports, brief communications, letters to the editor and invited review articles in the field of gastroenterology. The Journal is operated by internationally renowned editorial boards and designed to provide a global opportunity to promote academic developments in the field of gastroenterology and hepatology. Gut and Liver is jointly owned and operated by 8 affiliated societies in the field of gastroenterology, namely: the Korean Society of Gastroenterology, the Korean Society of Gastrointestinal Endoscopy, the Korean Society of Neurogastroenterology and Motility, the Korean College of Helicobacter and Upper Gastrointestinal Research, the Korean Association for the Study of Intestinal Diseases, the Korean Association for the Study of the Liver, the Korean Pancreatobiliary Association, and the Korean Society of Gastrointestinal Cancer.